GGrantIndex
← Search

PHASE II TRIAL OF CP336,156 FOR PREVENTION OF BONE LOSS IN POSTMENOPAUSAL WOMEN

$0M01FY2002RRNIH

Brigham And Women'S Hospital, Boston MA

Investigators

Linked publications & trials

Abstract

The purpose of this study is to compare the effects of 52 weeks administration of cp-336, 156 ( an estrogen agonist/antagonist) at 4 dose level, versus placebo on bone mineral density of the lumbar spine, hip, whole body, uterine endometrium, safety and toleration. Thyroid tests are done at this site only because they are investigator-initiated in order to obtain data in thyroid binding globulin levels. The main study is conducted elsewhere. Visits to GCRC ambulatory center for thyroid testing only. This site is over subscribed.

View original record on NIH RePORTER →